These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 29956783)

  • 21. Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
    Su J; Zhang XC; An SJ; Zhong WZ; Huang Y; Chen SL; Yan HH; Chen ZH; Guo WB; Huang XS; Wu YL
    Chin J Cancer; 2014 Jul; 33(7):346-50. PubMed ID: 24823994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
    Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
    BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
    Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M
    Cancer Sci; 2019 Oct; 110(10):3350-3357. PubMed ID: 31361375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
    Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
    Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.